Results 271 to 280 of about 1,709,620 (289)

Gifted Underachievement and its Dynamic Etiology [PDF]

, 2008
Perry, Stephanie L.
core   +1 more source

Synergistic Fluorine and Cyanide Co‐Modification to Reinforce Photoinduced Excitons Formation and Transfer for Efficient CO2 Photoreduction

Advanced Functional Materials, EarlyView.
An advanced F‐doped and ─CN group co‐modified FCCN is developed. Due to the synergistic effects of co‐modification in promoting photogenerated exciton generation, enhancing charge kinetics, expanding active interfacial areas, and optimizing CO2 interfacial reactions, the FCCN photocatalyst demonstrates excellent catalytic performance and high ...
Sheng‐Qi Guo, Qingqing Dong, Xiaodong Sun, Ziqi Zhang, Linda Wang, Lei Bao, Bozhan Li, Hui Li, Yanrui Li, Tianyi Ma   +9 more
wiley   +1 more source

Reconfigurable Magnetic Soft Microrobot for Acoustically Triggered Targeted Bacterial Sterilization

Advanced Functional Materials, EarlyView.
Reconfigurable magnetic soft microrobots integrate in situ‐grown piezoelectric zinc oxide nanorods that produce reactive oxygen species upon acoustic excitation. Combining magnetically guided transport with thermally induced planar reconfiguration, the microrobots achieve targeted delivery and enhanced bacterial sterilization through efficient on ...
Quan Gao, Fan Li, Jiajie Gao, Elric Zhang, Yingdong Su, Ni Qin, Hao Ye, Josep Puigmartí, Giuseppe Cantarella, Simone Schuerle, Jiang Wu, Bradley J. Nelson, Salvador Pané   +12 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval

The journal of prevention of Alzheimer's disease, 2023
Aducanumab is the first FDA-approved amyloid-lowering immunotherapy for Alzheimer’s disease. There is little real-world data to guide management of amyloid-related imaging abnormalities (ARIA), a potentially serious side-effect which requires ...
Matthew D. Howe, K. Britton, H. E. Joyce, G. J. Pappas, M. Faust, B. Dawson, M. Riddle, S. Salloway   +7 more
semanticscholar   +1 more source

Medicare Spending on Drugs With Accelerated Approval

Annals of Internal Medicine, 2022
BACKGROUND The U.S. Food and Drug Administration provides accelerated approval to drugs on the basis of surrogate end points deemed to be "reasonably likely" to predict clinical benefit. To receive full approval, drugs must complete a confirmatory trial.
Jeromie Ballreich, M. Socal, C. Bennett, M. Schoen, A. Trujillo, Andrew Xuan, G. Anderson   +6 more
semanticscholar   +1 more source

The FDA Struggle to Withdraw Makena: Problems With the Accelerated Approval Process.

Journal of the American Medical Association (JAMA), 2022
This Viewpoint discusses the controversy surrounding the FDA’s efforts to withdraw Makena from the market and the broader implications for the accelerated approval pathway.
Daniel G Aaron, I. G. Cohen, E. Adashi
semanticscholar   +1 more source

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Clinical Cancer Research, 2020
On April 22, 2020, the FDA granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY; Immunomedics, Inc.) for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for ...
S. Wahby, L. Fashoyin-Aje, C. Osgood, Joyce Cheng, M. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S Hamed, P. Song, R. Charlab, Sarah E Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, M. Theoret, R. Pazdur, L. Amiri-Kordestani, J. Beaver   +18 more
semanticscholar   +1 more source

Potential policy reforms to strengthen the accelerated approval pathway.

Journal of Comparative Effectiveness Research, 2021
The accelerated approval pathway for new drugs in the United States is often praised but faces growing criticism of whether it is finding the appropriate balance between uncertainty, access and cost.
A. Kaltenboeck, Amanda Mehlman, S. Pearson   +2 more
semanticscholar   +1 more source

Raising Medicaid Rebates For Drugs With Accelerated Approval.

Health Affairs, 2021
Through the Accelerated Approval Program, the Food and Drug Administration (FDA) may approve drugs that treat severe or life-threatening conditions on the basis of preliminary evidence of efficacy. Many of these drugs are made available at extremely high
Benjamin N. Rome, A. Kesselheim
semanticscholar   +1 more source

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review

JAMA Oncology, 2018
Importance Accelerated approval (AA) is a US Food and Drug Administration (FDA) expedited program intended to speed the approval of drugs and biologics that may demonstrate a meaningful advantage over available therapies for diseases that are serious or ...
J. Beaver, L. Howie, Lorraine C Pelosof, Tamy Kim, Jinzhong Liu, Kirsten B. Goldberg, R. Sridhara, G. Blumenthal, A. Farrell, P. Keegan, R. Pazdur, P. Kluetz   +11 more
semanticscholar   +1 more source